[Pimecrolimus (SDZ ASM 981). Current state of research].
Dissemond
J
J
Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Essen, Germany.
Goos
M
M
Wagner
S N
SN
D000279:Administration, Cutaneous; D000328:Adult; D000818:Animals; D002648:Child; D003879:Dermatologic Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D066298:In Vitro Techniques; D012867:Skin / Q000187:drug effects*; D012871:Skin Diseases / Q000188:drug therapy*; D016559:Tacrolimus / Q000009:adverse effects / Q000031:analogs & derivatives / Q000737:chemistry / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus